Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis, demonstrating a rapid onset of action and sustained responses with a favorable safety profile.1, 2, 3, 4. The gene discussed is IL17A; the disease is psoriatic arthritis.